Clinical Value of Acute Myeloblastic Leukemia 1-ETO Fusion Transcripts in Children with Acute Myeloblastic Leukemia by Using Real-Time Quantitative Reverse Transcriptase Polymerase Chain Reaction
- VernacularTitle:实时定量反转录聚合酶链反应检测患儿急性粒细胞性白血病1-ETO融合基因的临床意义
- Author:
yi-fei, CHENG
;
cai-feng, LIU
;
le-ping, ZHANG
;
ai-dong, LU
;
gui-lan, LIU
;
yan-rong, LIU
;
qiu-yue, YE
- Publication Type:Journal Article
- Keywords:
real-time reverse transcriptase polymerase chain reaction;
fusion gene;
acute myeloblastic leukemia;
child
- From:Journal of Applied Clinical Pediatrics
2006;0(15):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical value of minimal residual disease(MRD) of acute myeloblastic leukemia(AML) with AML 1-ETO by using the real-time quantitative reverse transcriptase polymerase chain reaction(RQ-RT-PCR).Methods From Jan.2001 to Jan.2007,the MRD of 32 AML1-ETO-positive AML patients were analyzed by using PQ-RT-PCR.The detection of the AML1-ETO was taken after the induced chemotherapy every 1.5-2.0 months during the consolidation therapy.The survival of different stages in children with AML was analyzed by SPSS 10.0 software and calculated by using Kaplan-Meier analysis.Results Thirty-two patients received the induced chemotherapy and 29 patients with complete remission morphologically,3 patients had no complete remission morphologically and then gave up.Patients with molecular remission were associated with a high probability of survival(P=0.001 8).Patients with high transcript levels at diagnosis had no difference in event free survival with patients with low transcript levels.The quality of molecular response after induction,6 months in the chemotherapy as well as consolidation period,has significant impact on the event free survival(P=0.023,0.000 1,0.004 9).Conclusion The current study demonstrate that quantitative evaluation of AML1-ETO transcript levels is important and may be helpful for therapeutic decisions in future.
